Investors take note of Opthea’s potential

Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more

MiSight continues to slow myopia

Five year results from the world’s longest-running clinical trial of paediatric contact lens wear has shown CooperVision’s MiSight 1 Day lens continues to slow myopia in children, even at older ages. Read more

New approach needed for AMD research

A working group assembled by the US National Advisory Eye Council (NAEC) has called for a change in strategy among researchers investigating potential cures for atrophic age-related macular degeneration (AMD). Read more